Rakesh Khator

Rakesh Khator

Auto-generated profile, based on publicly available information

Rakesh Khator

Central University of Punjab

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2023 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
NBNeha Bhatia
Neha Bhatia
RKRakesh Khator
Rakesh Khator
SKSwanand Kulkarni
Swanand Kulkarni
YSYogesh Singh
Yogesh Singh
PKPradeep Kumar
Pradeep Kumar
STSuresh Thareja
Suresh Thareja
Discovery of MDM2 and MDM2-p53 interaction inhibitors changed the direction of anticancer research as it is involved in about 50% of cancer cases globally. Not only the inhibition of MDM2 but also its interaction with p53 proved to be an effective strategy in anticancer drug design and development. Various molecules of natural as well as synthetic origin have been reported to possess excellent MDM2 inhibitory potential. The present review discusses the pathophysiology of the MDM2-p53 interaction loop and MDM2/MDM2-p53 interaction inhibitors from literature covering recent patents. Focus has also been put on characteristic features of the active site of the target and its desired interactions with the currently FDA-approved inhibitor. The designing approach of previously reported MDM2/MDM2-p53 interaction inhibitors, their SAR studies, in silico studies, and the biological efficacy of various inhibitors from natural as well as synthetic origins are also elaborated. An attempt is made to cover recently patented MDM2/MDM2- p53 interaction inhibitors.

17 January 2024 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
RKRakesh Khator
Rakesh Khator
VMVikramdeep Monga
Vikramdeep Monga
Diabetes is a serious health threat across the globe, claiming millions of lives worldwide. Among the various strategies employed, inhibition of α-amylase is a therapeutic protocol for the manageme... Graphical abstract

1 October 2024 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
RKRakesh Khator
Rakesh Khator
ABAvadh Biharee
Avadh Biharee
NBNeha Bhatia
Neha Bhatia
SKSwanand Kulkarni
Swanand Kulkarni
YSYogesh Singh
Yogesh Singh
STSuresh Thareja
Suresh Thareja
: Protein tyrosine phosphatase 1B (PTP1B) has gained interest as a therapeutic target for type 2 diabetes and obesity. Besides metabolic signalling, PTP1B is a positive regulator of signalling pathways linked to ErbB2-induced breast tumorigenesis. Substan-tial evidence proves that its overexpression is involved in breast cancer, which suggests that selective PTP1B inhibition might be effective in breast cancer treatment. Therefore, huge research is being carried out on PTP1B inhibitors and their activity against breast cancer development. To date, only two PTP1B inhibitors, viz. ertiprotafib and tro-dusquemine, have entered clinical trials. The discovery of selective inhibitors of PTP1B could open a new avenue in breast cancer treatment. In this review, we provide an exten-sive overview on the involvement of PTP1B in breast cancer, its pathophysiology, with special attention on the discovery and development of various natural as well as synthetic PTP1B inhibitors. This study will provide significant information to the researchers de-veloping PTP1B inhibitors for breast cancer treatment.

30 August 2025 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
VAVirendra Santosh Amrutkar
Virendra Santosh Amrutkar
RKRakesh Khator
Rakesh Khator
VMVikramdeep Monga
Vikramdeep Monga
Imidazo[2,1-b]thiazole represents a privileged heterocyclic moiety in medicinal chemistry which garnered huge attention among the researchers because of its extensive biological properties and ease of synthetic feasibility. Substituted imidazo[2,1-b]thiazole analogs with diverse therapeutic outcomes play a crucial role in the cure or management of various human ailments. The impact of this moiety in drug discovery can be realized from the fact that drugs based on this scaffold are used clinically. Medicinal and synthetic chemists have widely explored the chemical space around this scaffold for the generation of novel molecules capable of interacting with different biological targets of therapeutic concern. Due to its fascinating pharmacological profile, chemists have unfolded different facile and efficient synthetic protocols for imidazo[2,1-b]thiazole-based molecules. The present review highlights its outstanding role in drug discovery including different approaches for the synthesis of imidazo[2,1-b]thiazole hybrids. The recent advancements in the medicinal chemistry of imidazo[2,1-b]thiazole based analogs along with structure-activity relationships (SARs) and molecular docking studies have been compiled. The present review provides valuable insights for the design and development of imidazo[2,1-b]thiazole based bioactive agents as potential therapeutic candidates with desired efficacy and safety profile.